Although viral RNA or infectious virions have been detected in the feces of individuals infected with human influenza A and B viruses (IAV/IBV), the mechanism of viral survival in the gastrointestinal tract remains unclear. We developed a model that attempts to recapitulate the conditions encountered by a swallowed virus. While IAV/IBV are vulnerable to simulated digestive juices (gastric acid and bile/pancreatic juice), highly viscous mucus protects viral RNA and virions, allowing the virus to retain its infectivity. Our results suggest that virions and RNA present in swallowed mucus are not inactivated or degraded by the gastrointestinal environment, allowing their detection in feces.
The majority of patients infected with seasonal influenza A and B viruses (IAV/IBV) show upper respiratory tract symptoms and general symptoms [1] ; however, some individuals also have gastrointestinal symptoms [2] . Previous retrospective studies have detected IAV/IBV RNA in fecal samples from individuals in whom infectious enteritis was diagnosed after an upper respiratory infection [3] [4] [5] , and prospective observational studies detected IAV RNA in fecal samples from IAV-infected adults [2, 6] . Moreover, infectious virions have also been isolated from fecal samples [2, 7, 8] .
Although these findings suggest that IAV/IBV may infect the human intestinal tissue, the mechanism by which IAV/IBV retain their infectivity (defined on the basis of RNA detection) in feces remains unclear. Until this mechanism is elucidated, previous studies reporting IAV/IBV detection in feces should be interpreted with caution [9, 10] .
IAV/IBV are enveloped viruses that are rapidly inactivated by low pH and vulnerable to surfactants such as soap and bile [11] . Therefore, IAV/IBV are thought to be susceptible to gastric acid and bile, making it unlikely that infectious virions will reach the lower gastrointestinal tract to be excreted in the feces. Usually, the mucus secreted by cells lining the intestinal tract serves to clear respiratory viruses, including IAV/IBV [12] . However, we hypothesized that viscous sputum or nasal discharge may protect the virions from the gastric acid, bile, and pancreatic juices, allowing for intact viruses to pass through the intestinal tract and maintain their infectivity.
Here, we tested this hypothesis as the potential mechanism protecting swallowed IAV/IBV from degradation in the gastrointestinal tract, which could explain the reports of virus detection in feces. In particular, the presence of infectious IAV/IBV or viral RNA in fecal samples suggests that sputum protects the virus from degradation by digestive juices. Therefore, we evaluated the resistance of IAV RNA and infectious IAV/IBV in artificial mucus or sputum samples to simulated digestive juices. To this end, we developed a model to recapitulate the conditions encountered by a swallowed virus and exposed IAV/IBV to these conditions in the presence of artificial and natural mucus.
METHODS
Artificial mucus (guar gum or mucin from the porcine stomach) was prepared at different viscosities (10, 50, 100, 500, 1000, 2000, and 4000 mPa·s) at 37°C. Sputum samples were obtained from individuals in whom acute upper respiratory tract infection was diagnosed (ERB-C-634). The viscosity of the artificial mucus and sputum samples was measured using a Brookfield viscometer. The detailed methods are described in the Supplementary Materials.
In brief, 450 µL of simulated gastric acid (pH 2), simulated bile/pancreatic juice, or phosphate-buffered saline (PBS) was added to 50 µL of virus in artificial mucus or saline (final virus titer, 1.0 × 10 6 focus-forming units [FFU]/mL) and incubated at 37°C for 1, 2, or 4 hours. Next, 450 µL of simulated bile/pancreatic juice or PBS was added to 50 µL of virus in sputum samples, incubated at 37°C for 4 hours, and subjected to RNA extraction and quantitative polymerase chain reaction analysis [2] .
Moreover, 200 µL of simulated gastric acid (pH 2 or 3) or PBS was added to 50 µL of virus with artificial mucus or saline (final titer, 2.5 × 10 6 FFU/mL) and incubated at 37°C for 1 hour prior to neutralization with PBS (750 µL). Next, 200 µL of simulated bile/pancreatic juice or PBS was added to 200 µL of virus with artificial mucus or saline (final titer, 2.5 × 10 5 FFU/mL) and incubated at 37°C for 1, 2, or 4 hours before PBS addition (2400 µL), and the viral titers were determined. The inactivation test was also performed under a low-titer condition, and the relationship between the IAV titer and RNA copy number was evaluated.
The titer ratio (or RNA copy ratio) was calculated as the ratio of virus titer (or RNA copy number) in the simulated digestive juices to that in PBS, reflecting the proportion of the virus (or RNA) that is not inactivated or degraded.
RESULTS

Artificial Mucus Protects Viral RNA From Simulated Digestive Juices
In the presence of both saline and artificial mucus (guar gum or mucin from the porcine stomach), IAV RNA was resistant to simulated gastric acid even after prolonged (1-, 2-, 3-, or 4-hour) incubation ( Figure 1A ). However, IAV RNA was unstable in saline and low-viscosity (10 mPa·s) guar gum-based artificial mucus in the presence of simulated bile/pancreatic juice, as evidenced by a decrease of IAV RNA levels below the detection limit after 2 hours. In contrast, when IAV was incubated in the presence of relatively high-viscosity (100 and 1000 mPa·s) guar gum-based artificial mucus for 1, 2, or 4 hours, IAV RNA levels decreased over time but could be detected even after 4 hours. A similar trend was observed for IAV prepared in the mucin-based artificial mucus treated with simulated bile/pancreatic juice ( Figure 1B ). These results indicate that high-viscosity (100 and 1000 mPa·s) artificial mucus significantly protected IAV RNA from degradation by simulated bile/pancreatic juice (P < .001 for all comparisons).
Mucus From Sputum Samples Protects Viral RNA
The mean and median viscosities of 21 sputum samples were 995.2 mPa·s (range, 134.4-2294.1 mPa·s) and 1101.9 mPa·s (interquartile range, 414.3-1423.4 mPa·s), respectively ( Figure 1C ). IAV RNA was detected in all 21 sputum samples after 4 hours of incubation ( Figure 1D ), indicating similar protection of IAV RNA against digestive juices by artificial and natural mucus.
Artificial Mucus Protects Infectious Virions From Simulated Digestive Juices
First, we evaluated the resistance of IAV/IBV (virions) in artificial mucus to simulated gastric acid. Incubation with simulated gastric acid (pH 3) completely inactivated both IAV (subtypes H3N2 and H1N1) and IBV in low-viscosity mucus (10 and 50 mPa·s) and in saline. However, infectious viruses were detected in the samples with mucus viscosity ≥100 mPa·s, and the titer increased in proportion to the viscosity of the artificial mucus. After incubation in simulated gastric acid (pH 2), infectious viruses started to be detected at ≥1000 mPa·s, and the titer ratios increased with mucus viscosity, although they were lower than those at pH 3 ( Figure 2A ).
When viruses were mixed with mucin and simulated gastric acid (pH 3), infectious viruses were detected at ≥50 mPa·s, and the titer ratios increased with mucus viscosity. A similar pattern was observed for the simulated gastric acid at pH 2, although the virus titer ratios were slightly lower ( Figure 2B) .
Next, the resistance of IAV/IBV (virions) in artificial mucus to simulated bile/pancreatic juice was evaluated. When viruses were incubated in guar gum and simulated bile/pancreatic juice for 1 hour, both IAV (subtypes H3N2 and H1N1) and IBV were completely inactivated in saline, as well as in mucus with viscosities of 10, 50, 100, and 500 mPa·s. However, infectious viruses were detected at ≥1000 mPa·s, and the titer ratio increased with mucus viscosity, reaching ≥0.05 at 2000 mPa·s for both viruses. A similar pattern was observed after incubation under the same conditions for 2 or 4 hours but with slightly reduced titer ratios ( Figure 2C ).
When the viruses were mixed with mucin and incubated in simulated bile/pancreatic juice for 1 hour, infectious viruses were detected at ≥100 mPa·s, and the titer ratio increased with mucus viscosity, reaching ≥0.1 at 2000 mPa·s for both viruses. As above, a similar pattern was observed with longer incubation (2 or 4 hours) with slightly reduced titer ratios ( Figure 2D ). Overall, these findings indicate that IAV/IBV remain infectious in mucus even after prolonged exposure to bile/pancreatic juice.
Finally, we determined the same pattern of resistance acquisition by IAV in artificial mucus to simulated digestive juices under a low-titer condition (Supplementary Figure 1) . Moreover, in the inactivation test, the IAV RNA copy number was approximately 10-100 times the virus titer under the same conditions (Supplementary Figure 2) .
Discussion
The 4 principal findings of the present study are as follows: (1) although viral RNA was resistant to simulated gastric acid for 4 hours, it was degraded in simulated bile/pancreatic juice after 2 hours; (2) highly viscous artificial or natural (sputum) mucus protected viral RNA from degradation by simulated bile/pancreatic juice for >4 hours; (3) infectious virions (IAV/IBV) were vulnerable to simulated digestive juices (gastric acid and bile/ pancreatic juice); and (4) highly viscous artificial mucus protected virions from degradation by simulated digestive juices, as evidenced by their maintained infectivity.
IAV and IBV are vulnerable to external environmental factors and are considered to become quickly inactivated and degraded in the gastrointestinal tract by gastric acid and bile/pancreatic juice [10] , which should make the virus undetectable in feces. Indeed, our study showed that IAV and IBV were quickly inactivated, and viral RNA was completely degraded and undetectable within 2 hours of incubation with simulated digestive juice. Since it takes at least 2 hours for ingested food to pass through the small intestine [13] , even if high-titer IAV/IBV is swallowed, virions and their RNA should be completely inactivated and degraded in the intestine and should not be detectable in feces.
Therefore, a swallowed virus would only be detected in feces if certain protective mechanisms render it resistant to degradation in the gastrointestinal tract.
Here, we discovered that IAV/IBV become resistant to simulated gastric acid and bile/pancreatic juice in the surroundings of artificial mucus with a relatively high viscosity. The viral RNA copy ratio was calculated as the ratio of the RNA copy number in simulated digestive juices to that in phosphate-buffered saline (PBS). C, Viscosity of 21 sputum samples measured using a Brookfield viscometer. IQR, interquartile range. D, IAV subtype H3N2 and 21 sputum samples were incubated with simulated bile/ pancreatic juice at 37°C for 4 hours. Data are means ± SD, based on at least 3 independent experiments. P, positive control (PBS added to virus/sputum); N, negative control (simulated bile/pancreatic juice added to virus/saline); UD, undetectable. *P < .001 vs. saline.
To mimic viscoelastic body fluids such as sputum and nasal discharge, we created artificial mucus by using several types of solutes, which allowed us to exclude confounding factors (eg, solute properties). Even in the presence of simulated bile/ pancreatic juice, which reproduced the harsh gastrointestinal environment, viral RNA contained in the artificial mucus (imitating sputum, nasal discharge, and other mucous membrane secretions) was not degraded and could be detected after >4 hours. Furthermore, IAV/IBV maintained in the artificial mucus were not inactivated and retained its infectivity for at least 4 hours. When IAV/IBV infect and replicate in the upper respiratory tract, mucus (sputum and nasal H1N1 ) and IBV mixed with guar gum-based artificial mucus (A) or mucin from the porcine stomach (B) were incubated for 1 hour in simulated gastric acid prepared at pH 3 (upper panels) or pH 2 (lower panels). C and D, IAV and IBV mixed with guar gum-based artificial mucus (C) or mucin from the porcine stomach (D) were incubated for 1 hours (upper panels), 2 hours (middle panels), or 4 hours (lower panels) in simulated bile/pancreatic juice. The titer ratio was calculated as the ratio of the virus titer in simulated digestive juices to that in phosphate-buffered saline (PBS). Data are means ± SD, based on at least 3 independent experiments. discharge) containing high-titer viruses would be swallowed, and our results suggest that the virions and RNA are not inactivated/degraded by the gastrointestinal juices, which might be detectable in feces.
In the present study, mucus of a relatively high viscosity (≥100 mPa·s) was required for IAV/IBV to resist inactivation and degradation in the gastrointestinal environment (gastric acid or bile/pancreatic juice). Moreover, a viscosity of 100-1000 mPa·s was needed for the virions to maintain their infectivity in the presence of gastric acid or bile/pancreatic juice. All 21 sputum samples containing natural mucus with a viscosity of ≥100 mPa·s protected viral RNA from degradation by simulated bile/pancreatic juice. These results suggest a protective effect of artificial mucus, since the correlation between virus survival and mucus viscosity was similar for the artificial and natural mucus. Despite the assumed vulnerability of IAV/IBV to external conditions, several studies have suggested that retention of virus infectivity was possible for hours to days, depending on environmental conditions [14] . Our results show that the viscosity of the medium surrounding IAV/IBV directly affects the ability of the virus to resist harsh external environments, providing a foundation for further research on the relationship between viral protection and mucus viscosity.
We modeled the natural situation of swallowing sputum or nasal discharge containing high-titer IAV/IBV, which occurs upon virus infection and proliferation in the upper respiratory tract. Our results provide an explanation for the detection of viral RNA and infectious virions in the feces of individuals infected with IAV/IBV. Previous studies reporting the fecal detection of virions and viral RNA suggested that the virus presence was not merely due to contamination but indicated its passage through the gastrointestinal tract after oral invasion and subsequent swallowing [2] [3] [4] [5] [6] [7] [8] . Our results support this theory by demonstrating that viscous mucus protects IAV/IBV from inactivation in the gastrointestinal environment, accounting for detection of the virus in feces.
Moreover, avian influenza virus (A[H5N1]) was demonstrated to be capable of infecting the intestine [15] , suggesting the same potential for IAV/IBV. Since this transmission pathway would enable the virus protected by the mucus to reach intestinal epithelial cells, it could be a major contributor to intestinal IAV/IBV infection in humans. We are currently developing a model to evaluate the possibility of intestinal IAV/IBV infection.
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